
Treatment of pulmonary zzso hypertension zzso 1 of clinical zzso has been recently characterized by important progresses, particularly in pharmacological zzso Only until few years ago, patients with pulmonary zzso hypertension were treated with zzso drugs, such as zzso and zzso for right heart failure and zzso zzso in the minority of cases, zzso to the acute zzso zzso In addition, use of oral zzso treatment was supported by uncontrolled zzso In the last 15 years (in particular in the last 8 zzso different zzso controlled trials assessing the functional, clinical and zzso efficacy of three classes of targeted drugs zzso zzso zzso zzso and zzso type 5 zzso with pulmonary vascular zzso and zzso effects have been zzso This information has allowed the proposal of an evidence-based treatment zzso Treatment starts with general measures (physical activity, fertility control, respiratory tract infection, zzso and supportive therapy zzso therapy, zzso zzso zzso Patients who respond to the acute zzso test zzso of idiopathic zzso are treated with high doses of zzso blockers, zzso with targeted therapies either on zzso or zzso Usually an oral active drug is initiated and a second compound of a different class is combined in case of zzso response to the first zzso Combination therapy should be performed only in specialized centers with large experience on use of targeted therapies and their relevant side zzso In case of failure of medical therapy, possible options are balloon zzso zzso and/or listing for lung or zzso zzso As available treatments do not constitute a cure for pulmonary zzso hypertension, further zzso are expected in the near zzso 

